Immuneering (IMRX) Cash & Equivalents (2020 - 2024)
Historic Cash & Equivalents for Immuneering (IMRX) over the last 5 years, with Q3 2024 value amounting to $45.2 million.
- Immuneering's Cash & Equivalents fell 3356.06% to $45.2 million in Q3 2024 from the same period last year, while for Sep 2024 it was $45.2 million, marking a year-over-year decrease of 3356.06%. This contributed to the annual value of $59.4 million for FY2023, which is 1821.54% down from last year.
- Immuneering's Cash & Equivalents amounted to $45.2 million in Q3 2024, which was down 3356.06% from $59.7 million recorded in Q2 2024.
- Immuneering's Cash & Equivalents' 5-year high stood at $106.9 million during Q3 2021, with a 5-year trough of $37.1 million in Q4 2020.
- Its 5-year average for Cash & Equivalents is $70.8 million, with a median of $72.6 million in 2022.
- Per our database at Business Quant, Immuneering's Cash & Equivalents surged by 10190.84% in 2021 and then tumbled by 4257.85% in 2024.
- Quarter analysis of 5 years shows Immuneering's Cash & Equivalents stood at $37.1 million in 2020, then surged by 101.91% to $74.9 million in 2021, then decreased by 3.01% to $72.6 million in 2022, then fell by 18.22% to $59.4 million in 2023, then decreased by 23.9% to $45.2 million in 2024.
- Its Cash & Equivalents was $45.2 million in Q3 2024, compared to $59.7 million in Q2 2024 and $66.3 million in Q1 2024.